Poolbeg Pharma has in-licensed a late preclinical-stage, potentially broad-spectrum treatment for respiratory virus infections, representing the second expansion of its R&D pipeline in as many months. The new agent is a nasally-administered RNA-based approach with prophylactic and therapeutic a
17 Jan 2022
Poolbeg expands R&D portfolio
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Poolbeg expands R&D portfolio
Poolbeg Pharma PLC (POLB:LON) | 9.6 0 (-0.5%) | Mkt Cap: 48.2m
- Published:
17 Jan 2022 -
Author:
Robin Davison -
Pages:
3
Poolbeg Pharma has in-licensed a late preclinical-stage, potentially broad-spectrum treatment for respiratory virus infections, representing the second expansion of its R&D pipeline in as many months. The new agent is a nasally-administered RNA-based approach with prophylactic and therapeutic a